ScholarIQanswers from OpenAlex & ORCID
Bert H. O’Neil
ResearcherPublications, citations & collaboration network
Bert H. O’Neil is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Bert H. O’Neil have?
ScholarIQindexed works
Bert H. O’Neil has 470 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Bert H. O’Neil have?
ScholarIQcitation count
Bert H. O’Neil has 17,304 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Bert H. O’Neil?
ScholarIQh-index
Bert H. O’Neil has an h-index of 60 in OpenAlex.
What is the i10-index of Bert H. O’Neil?
ScholarIQi10-index
Bert H. O’Neil has an i10-index of 178 in OpenAlex.
What is the ORCID of Bert H. O’Neil?
ScholarIQorcid
The ORCID for Bert H. O’Neil is on the source record.
What is the OpenAlex record for Bert H. O’Neil?
ScholarIQopenalex
The OpenAlex for Bert H. O’Neil is on the source record.
What are the most-cited papers on Bert H. O’Neil?
ScholarIQmost cited works
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal Cancer
Alan P. Venook, Donna Niedzwiecki, Heinz‐Josef Lenz, Federico Innocenti, Briant Fruth, Jeffrey A. Meyerhardt, Deborah Schrag, Claire Greene, Bert H. O’Neil, James N. Atkins, Scott Berry, Blasé N. Polite, Eileen M. O’Reilly, Richard M. Goldberg, Howard S. Höchster, Richard L. Schilsky, Monica M. Bertagnolli, Anthony B. El-Khoueiry, Peter J. Watson, Al B. Benson, Daniel Mulkerin, Robert J. Mayer, Charles D. Blanke
Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas
Howard A. Burris, Herbert I. Hurwitz, Elizabeth Claire Dees, Afshin Dowlati, Kimberly Blackwell, Bert H. O’Neil, P. Kelly Marcom, Matthew J. Ellis, Beth Overmoyer, Suzanne F. Jones, Jennifer L. Harris, Deborah A. Smith, Kevin M. Koch, Andrew G. Stead, Steve Mangum, Neil L. Spector
Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma
Bert H. O’Neil, John M. Wallmark, David Lorente, Elena Élez, Judith Raimbourg, Carlos Gomez‐Roca, Samuel Ejadi, Sarina A. Piha‐Paul, Mark N. Stein, Albiruni R. Abdul Razak, Katia Dotti, Armando Santoro, Roger B. Cohen, M. Gould, Sanatan Saraf, Karen Stein, Sae‐Won Han